Centers for Medicare and Medicaid Services Shines Amidst Turmoil

The Centers for Medicare and Medicaid Services (CMS) has emerged as a leading agency in the realm of health care reform during the early months of the Trump administration’s second term. While other health agencies, such as the Food and Drug Administration, have faced challenges, CMS has taken significant steps to innovate and improve health care delivery in the United States.

Under the authority of CMS, which oversees approximately $1.7 trillion in health care services—accounting for 24% of the federal budget—the agency has focused on enhancing access to care and addressing systemic inefficiencies. In stark contrast to the turmoil evident in other federal health agencies, CMS has maintained a nonpartisan focus, striving to implement meaningful reforms.

The departure of around 50,000 employees from the Department of Veterans Affairs has exacerbated delays for veterans seeking care, highlighting the broader staffing issues affecting federal health agencies. Additionally, the controversial changes to the childhood vaccine schedule proposed by Health Secretary Robert F. Kennedy Jr. have raised serious health concerns. Nevertheless, CMS has managed to navigate these challenges, positioning itself as a beacon of progress amid a difficult landscape.

Innovative Strategies and Financial Reforms

CMS has made commendable strides in strengthening primary care, a critical component of the U.S. health system. Recently, the agency increased compensation for primary care physicians while reducing payments for specialists, an approach long advocated by health experts. Although the pay increase is modest, it sends a positive signal regarding the future of primary care.

Another significant initiative is the expansion of site-neutral payments, which aims to standardize reimbursement rates for similar services provided in different settings. For example, a hip replacement performed in a hospital can cost nearly $3,500 more than in an ambulatory surgical center. By addressing these discrepancies, CMS estimates that transitioning care to lower-cost settings could save the government up to $100 billion annually without compromising quality.

CMS has recently expanded site-neutral payments for drug administration services, including chemotherapy and immunotherapies, a move praised by experts as a step toward comprehensive payment reform. According to the Kaiser Family Foundation’s Zachary Levinson, this shift represents progress, albeit modest compared to more extensive proposals discussed by the Medicare Payment Advisory Committee (MedPAC).

In what may come as a surprise, CMS proposed a minimal payment increase of just 0.09% (approximately $700 million) for Medicare Advantage plans in 2027, a drastic reduction compared to last year’s increase of over 5% (approximately $25 billion). This decision indicates a shift in the administration’s approach to private insurers, who have been criticized for exploiting the Medicare Advantage system through practices such as “upcoding” which inflates payments.

MedPAC estimates that these practices may result in overpayments exceeding $75 billion annually. The announcement of a negligible payment increase led to a loss of nearly $100 billion in market value for major Medicare Advantage companies, signaling a commitment by CMS to curb waste and ensure fiscal responsibility.

Future Directions and Ongoing Challenges

The CMS Innovation Center continues to build on successful models from previous administrations, introducing initiatives to enhance care quality while controlling costs. One notable initiative is the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model, which seeks to leverage artificial intelligence in managing chronic conditions such as hypertension and diabetes—responsible for approximately one million deaths annually. This model emphasizes payment based on patient outcomes rather than sheer service delivery, a shift that could redefine health care economics.

Another significant development is the Wasteful and Inappropriate Service Reduction (WISeR) model, which introduces prior authorization for a select group of high-cost medical services. While prior authorization has faced public scrutiny, the model addresses specific areas of fraud and abuse, particularly concerning skin substitutes, which have seen a dramatic increase in costs from $252 million in 2019 to an estimated $15 billion in 2025.

Despite these positive advancements, CMS has not been without controversy. The recent rescinding of Biden-era guidance on emergency abortion care has raised legal uncertainties for health providers, reflecting the ongoing political tensions surrounding health care policy.

Polling indicates that health care costs remain the top concern for American households, surpassing other significant expenses. As the U.S. health care system approaches a critical juncture, the need for comprehensive affordability reforms will be crucial, regardless of which administration takes office in 2029.

In summary, while challenges persist across various federal health agencies, the proactive measures taken by CMS demonstrate a commitment to improving the health care landscape. The agency’s focus on primary care, financial reform, and innovation positions it as a vital player in the ongoing efforts to enhance health care access and quality in the United States. The actions of CMS warrant recognition, especially amid the struggles faced by many other health agencies.